Stay updated on Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial
Sign up to get notified when there's something new on the Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial page.

Latest updates to the Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoChange DetectedThe history page shows newer version entries and metadata updates, while the core study details remain unchanged.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check41 days agoChange DetectedDifference12%

- Check48 days agoChange DetectedPage update: new date and study identifiers added (v3.1.0), replacing older date and revision (v3.0.2).SummaryDifference2%

- Check63 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2. The only other visible change is the removal of the 'Back to Top' link, a minor UI cleanup with no substantive changes to content, pricing, stock, or time slots.SummaryDifference0.7%

- Check70 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.7%

- Check77 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location details, while several location-related terms have been removed.SummaryDifference13%

Stay in the know with updates to Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial page.